HAEM5:B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion: Difference between revisions

(View all pending changes)

[pending revision]

← Older edit

VisualWikitext

@@ Line 62: / Line 62: @@
 T: N/A
-P: Too few cases to  accurately assess prognosis
+P: Too few cases to  accurately assess prognosis; however, A small case series suggested an intermediate prognosis, with a poor response to treatment and high levels of measurable residual disease at the end of induction<ref>{{Cite journal|last=Fournier|first=Benjamin|last2=Balducci|first2=Estelle|last3=Duployez|first3=Nicolas|last4=Clappier|first4=Emmanuelle|last5=Cuccuini|first5=Wendy|last6=Arfeuille|first6=Chloé|last7=Caye-Eude|first7=Aurélie|last8=Delabesse|first8=Eric|last9=Bottollier-Lemallaz Colomb|first9=Elodie|date=2019|title=B-ALL With t(5;14)(q31;q32); IGH-IL3 Rearrangement and Eosinophilia: A Comprehensive Analysis of a Peculiar IGH-Rearranged B-ALL|url=https://pubmed.ncbi.nlm.nih.gov/31921638|journal=Frontiers in Oncology|volume=9|pages=1374|doi=10.3389/fonc.2019.01374|issn=2234-943X|pmc=6914849|pmid=31921638}}</ref>.
 |No (NCCN)
-|A small case series suggested an intermediate prognosis, with a poor response to treatment and high levels of measurable residual disease at the end of induction<ref>{{Cite journal|last=Fournier|first=Benjamin|last2=Balducci|first2=Estelle|last3=Duployez|first3=Nicolas|last4=Clappier|first4=Emmanuelle|last5=Cuccuini|first5=Wendy|last6=Arfeuille|first6=Chloé|last7=Caye-Eude|first7=Aurélie|last8=Delabesse|first8=Eric|last9=Bottollier-Lemallaz Colomb|first9=Elodie|date=2019|title=B-ALL With t(5;14)(q31;q32); IGH-IL3 Rearrangement and Eosinophilia: A Comprehensive Analysis of a Peculiar IGH-Rearranged B-ALL|url=https://pubmed.ncbi.nlm.nih.gov/31921638|journal=Frontiers in Oncology|volume=9|pages=1374|doi=10.3389/fonc.2019.01374|issn=2234-943X|pmc=6914849|pmid=31921638}}</ref>.
+|Clinical presentations vary widely. Some patients present with a typical B-ALL/LBL phenotype characterized by elevated blasts, while others exhibit only asymptomatic eosinophilia with minimal or no circulating blasts. In additional cases, the disease manifests as hypereosinophilic syndrome, featuring organomegaly, respiratory symptoms, cutaneous lesions, neurologic findings, thrombotic events, or eosinophilic cardiac involvement<ref>{{Cite journal|last=Tono-oka|first=T.|last2=Sato|first2=Y.|last3=Matsumoto|first3=T.|last4=Ueno|first4=N.|last5=Ohkawa|first5=M.|last6=Shikano|first6=T.|last7=Takeda|first7=T.|date=1984|title=Hypereosinophilic syndrome in acute lymphoblastic leukemia with a chromosome translocation [t(5q;14q)]|url=https://pubmed.ncbi.nlm.nih.gov/6583469|journal=Medical and Pediatric Oncology|volume=12|issue=1|pages=33–37|doi=10.1002/mpo.2950120109|issn=0098-1532|pmid=6583469}}</ref><ref>{{Cite journal|last=Fournier|first=Benjamin|last2=Balducci|first2=Estelle|last3=Duployez|first3=Nicolas|last4=Clappier|first4=Emmanuelle|last5=Cuccuini|first5=Wendy|last6=Arfeuille|first6=Chloé|last7=Caye-Eude|first7=Aurélie|last8=Delabesse|first8=Eric|last9=Bottollier-Lemallaz Colomb|first9=Elodie|date=2019|title=B-ALL With t(5;14)(q31;q32); IGH-IL3 Rearrangement and Eosinophilia: A Comprehensive Analysis of a Peculiar IGH-Rearranged B-ALL|url=https://pubmed.ncbi.nlm.nih.gov/31921638|journal=Frontiers in Oncology|volume=9|pages=1374|doi=10.3389/fonc.2019.01374|issn=2234-943X|pmc=6914849|pmid=31921638}}</ref><ref>{{Cite journal|last=Toboso|first=Dolores Gómez|last2=Campos|first2=Carmen Benet|date=2017-07-20|title=Peripheral eosinophilia as the first manifestation of B-cell acute lymphoblastic leukemia with t(5;14)(q31;q32)|url=https://pubmed.ncbi.nlm.nih.gov/28729339|journal=Blood|volume=130|issue=3|pages=380|doi=10.1182/blood-2016-12-754812|issn=1528-0020|pmid=28729339}}</ref>.
 |}